These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9520516)

  • 1. Preventing and reversing target organ damage by treatment of the renin-angiotensin system.
    Krakoff LR; Rajasekharaiah V
    Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516
    [No Abstract]   [Full Text] [Related]  

  • 2. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin converting enzyme inhibitors in arterial hypertension].
    Ramón González-Juanatey J
    Rev Esp Cardiol; 1999; 52 Suppl 3():73-8. PubMed ID: 10614152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG
    Clin Ther; 2008; 30 Pt 2():2181-90. PubMed ID: 19281913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin-converting enzyme inhibitors. Principles and rules of their use].
    Juillière Y
    Rev Prat; 2001 Sep; 51(14):1601-7. PubMed ID: 11757278
    [No Abstract]   [Full Text] [Related]  

  • 16. Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation.
    Dawood T; Schlaich MP
    Minerva Cardioangiol; 2009 Dec; 57(6):687-704. PubMed ID: 19942842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention.
    Gradman AH
    Am Heart J; 2009 Jun; 157(6 Suppl):S1-6. PubMed ID: 19450719
    [No Abstract]   [Full Text] [Related]  

  • 19. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct renin inhibition: a new and promising treatment principle in heart failure?].
    Mahfoud F; Ukena C; Böhm M
    Dtsch Med Wochenschr; 2009 Apr; 134(15):759-62. PubMed ID: 19340755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.